Who are RIFAMPIN's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): rifapentine and moxifloxacin, Rifadin, Xifaxan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rifampin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

RIFAMPIN — Competitive Intelligence Brief

RIFAMPIN (RIFAMPIN) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rifamycin Antibacterial [EPC]. Area: Infectious Disease.

marketed Rifamycin Antibacterial [EPC] DNA-dependent RNA polymerase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

RIFAMPIN (RIFAMPIN). Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible Mycobacterium tuberculosis organisms.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RIFAMPIN TARGET	RIFAMPIN		marketed	Rifamycin Antibacterial [EPC]	DNA-dependent RNA polymerase	1971-01-01
rifapentine and moxifloxacin	rifapentine and moxifloxacin	Centers for Disease Control and Prevention	phase 3	fluoroquinolone	DNA-dependent RNA polymerase, DNA gyrase, topoisomerase IV
Rifadin	Rifampicin	Sanofi Aventis Us	marketed	Rifamycin Antibacterial [EPC]	Solute carrier organic anion transporter family member 1A2, ATP-binding cassette sub-family G member 2, Alpha-synuclein	1971-01-01
Xifaxan	rifaximin	Bausch Health	marketed	Rifamycin Antibacterial [EPC]	Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-09-02 — Xifaxan · 8193196 · Compound · US
2029-02-26 — Xifaxan · 11564912 · Method of Use · US
2029-02-26 — Xifaxan · 10456384 · Method of Use · US
2029-02-26 — Xifaxan · 11779571 · Method of Use · US
2029-02-26 — Xifaxan · 10765667 · Method of Use · US
2029-07-18 — Xifaxan · 8309569 · Method of Use · US
2029-07-24 — Xifaxan · 10314828 · Method of Use · US
2029-07-24 — Xifaxan · 10709694 · Method of Use · US
2029-07-24 — Xifaxan · 10335397 · Method of Use · US
2029-07-24 — Xifaxan · 8829017 · Method of Use · US
2029-07-24 — Xifaxan · 9421195 · Method of Use · US
2029-07-24 — Xifaxan · 8946252 · Method of Use · US
2029-07-24 — Xifaxan · 7928115 · Method of Use · US
2029-07-24 — Xifaxan · 9629828 · Method of Use · US
2029-10-02 — Xifaxan · 8969398 · Method of Use · US
2029-10-02 — Xifaxan · 8642573 · Method of Use · US

Sponsor landscape (Rifamycin Antibacterial [EPC] class)

· 1 drug in this class
Bausch Health · 1 drug in this class
Sanofi Aventis Us · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RIFAMPIN — Competitive Intelligence Brief. https://druglandscape.com/ci/rifampin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab